{"id":28092,"date":"2014-08-13T07:38:09","date_gmt":"2014-08-13T11:38:09","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=28092"},"modified":"2014-08-13T07:38:09","modified_gmt":"2014-08-13T11:38:09","slug":"exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092","title":{"rendered":"EXACT Sciences Corporation (NASDAQ:EXAS) One Of Its Kind, Stood DNA Non-Invasive Screening Test For Colorectal Cancer Gets FDA Nod"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 08\/13\/2014 (wallstreetpr) \u2013\u00a0<b>EXACT Sciences Corporation (NASDAQ:EXAS)<\/b> on August 12, 2014 announced that the U.S. Food and Drug Administration (FDA) gave its approval to <a href=\"http:\/\/finance.yahoo.com\/news\/fda-approves-exact-sciences-cologuard-110000539.html\"><b>Cologuard<\/b><\/a>. This is the non-invasive, stool DNA cancer screening test of the company and also the first such screening test for colorectal cancer, capable of analyzing not just stool DNA, but also blood biomarkers.<\/p>\n<p style=\"text-align: justify;\"><b>About Cologuard<\/b><\/p>\n<p style=\"text-align: justify;\">It has been found that Cologuard can diagnose around 92% of cancers as well as 69% of most advanced precancerous polyps among even the average risk patients. This test is also available through healthcare providers with ease and allows people of the age 50 years and above, the access to easily accessible and used screening test which can be done in the privacy of home only.<\/p>\n<p style=\"text-align: justify;\"><b>CMS Proposed Coverage Memorandum<\/b><\/p>\n<p style=\"text-align: justify;\">After the screening test got approval from the FDA, EXACT Sciences Corporation (NASDAQ:EXAS)\u00a0also proposed coverage memorandum from Centers for Medicare and Medicaid Services, abbreviated as CMS. It is worth noticing that Cologuard is the first of its kind product which participates in the parallel review pilot program of FDA and CMS jointly. Both these agencies will now, side by side make a review of the medical devices in order to assist in bringing down the time duration between Medicare coverage as well as FDA approval.<\/p>\n<p style=\"text-align: justify;\">In this regard, the final National Coverage Determination shall be posted in October or November 2014.<\/p>\n<p style=\"text-align: justify;\"><b>Statement from the Co-Inventor of Drug<\/b><\/p>\n<p style=\"text-align: justify;\">The gastroenterologist as well as the co-inventor of Cologuard test, <i>David Ahlquist<\/i> said that the strong research which was conducted in order to seek FDA approval, proved that this type of non-invasive test is very sensitive for detection of colorectal cancer at an early stage along with the diagnosis of advanced precancerous polyps, which may develop in the cancer. He added that the test has been designed for higher accuracy as well as easy use of the patients. It also offers wider accessibility.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 08\/13\/2014 (wallstreetpr) \u2013\u00a0EXACT Sciences Corporation (NASDAQ:EXAS) on August 12, 2014 announced that the U.S. Food and Drug Administration (FDA) gave its approval to [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":20398,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[6123,6124],"stock_ticker":[],"class_list":["post-28092","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-exact-sciences-corporation-nasdaqexas","tag-nasdaqexas","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>EXACT Sciences Corporation (NASDAQ:EXAS) One Of Its Kind, Stood DNA Non-Invasive Screening Test For Colorectal Cancer Gets FDA Nod  - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EXACT Sciences Corporation (NASDAQ:EXAS) One Of Its Kind, Stood DNA Non-Invasive Screening Test For Colorectal Cancer Gets FDA Nod  - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 08\/13\/2014 (wallstreetpr) \u2013\u00a0EXACT Sciences Corporation (NASDAQ:EXAS) on August 12, 2014 announced that the U.S. Food and Drug Administration (FDA) gave its approval to [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-08-13T11:38:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/EXACT-Sciences-Corporation.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"960\" \/>\n\t<meta property=\"og:image:height\" content=\"350\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"EXACT Sciences Corporation (NASDAQ:EXAS) One Of Its Kind, Stood DNA Non-Invasive Screening Test For Colorectal Cancer Gets FDA Nod\",\"datePublished\":\"2014-08-13T11:38:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092\"},\"wordCount\":338,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/EXACT-Sciences-Corporation.jpg\",\"keywords\":[\"EXACT Sciences Corporation (NASDAQ:EXAS)\",\"NASDAQ:EXAS\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092\",\"name\":\"EXACT Sciences Corporation (NASDAQ:EXAS) One Of Its Kind, Stood DNA Non-Invasive Screening Test For Colorectal Cancer Gets FDA Nod - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/EXACT-Sciences-Corporation.jpg\",\"datePublished\":\"2014-08-13T11:38:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/EXACT-Sciences-Corporation.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/EXACT-Sciences-Corporation.jpg\",\"width\":960,\"height\":350},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EXACT Sciences Corporation (NASDAQ:EXAS) One Of Its Kind, Stood DNA Non-Invasive Screening Test For Colorectal Cancer Gets FDA Nod\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EXACT Sciences Corporation (NASDAQ:EXAS) One Of Its Kind, Stood DNA Non-Invasive Screening Test For Colorectal Cancer Gets FDA Nod  - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092","og_locale":"en_US","og_type":"article","og_title":"EXACT Sciences Corporation (NASDAQ:EXAS) One Of Its Kind, Stood DNA Non-Invasive Screening Test For Colorectal Cancer Gets FDA Nod  - Wall Street PR","og_description":"Boston, MA 08\/13\/2014 (wallstreetpr) \u2013\u00a0EXACT Sciences Corporation (NASDAQ:EXAS) on August 12, 2014 announced that the U.S. Food and Drug Administration (FDA) gave its approval to [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-08-13T11:38:09+00:00","og_image":[{"width":960,"height":350,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/EXACT-Sciences-Corporation.jpg","type":"image\/jpeg"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"EXACT Sciences Corporation (NASDAQ:EXAS) One Of Its Kind, Stood DNA Non-Invasive Screening Test For Colorectal Cancer Gets FDA Nod","datePublished":"2014-08-13T11:38:09+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092"},"wordCount":338,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/EXACT-Sciences-Corporation.jpg","keywords":["EXACT Sciences Corporation (NASDAQ:EXAS)","NASDAQ:EXAS"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092","url":"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092","name":"EXACT Sciences Corporation (NASDAQ:EXAS) One Of Its Kind, Stood DNA Non-Invasive Screening Test For Colorectal Cancer Gets FDA Nod - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/EXACT-Sciences-Corporation.jpg","datePublished":"2014-08-13T11:38:09+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/EXACT-Sciences-Corporation.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/EXACT-Sciences-Corporation.jpg","width":960,"height":350},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/exact-sciences-corporation-nasdaqexas-one-of-its-kind-stood-dna-non-invasive-screening-test-for-colorectal-cancer-gets-fda-nod-28092#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"EXACT Sciences Corporation (NASDAQ:EXAS) One Of Its Kind, Stood DNA Non-Invasive Screening Test For Colorectal Cancer Gets FDA Nod"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/28092","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=28092"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/28092\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/20398"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=28092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=28092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=28092"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=28092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}